Objectives: Systemic lupus erythematosus (SLE) shows a strong sex bias, preferentially affecting females, and B cells are thought to play a pivotal role in its pathogenesis. Here, we compared the splenic B-cell compartments, their autoreactivity and activation threshold of female and male NZB/W F1, a murine lupus model reflecting the sex bias observed in patients with SLE. Methods: Autoantibody levels and the amount of autoantibody secreting cells were determined using ELISA and ELISPOT. Flow cytometry and immunofluorescence were applied to analyse the composition of the splenic B-cell pool. Purified follicular (FO) and marginal zone (MZ) B cells were stimulated and the frequency of autoreactive cells was determined. Finally, the proliferative response of FO and MZ B cells upon stimulation was assessed using CFSE dilution and [ 3 H]-Thymidin incorporation. Results: Higher autoantibody titres were detected in female NZB/W F1 mice, which were mainly produced in the spleen. Analysing the composition of the splenic B-cell subsets, no differences were found prior to disease development. Autoreactive dsDNA-specific B cells were mostly found in the MZ compartment, while SmD1 (83-119) -reactive cells were more evenly distributed. Equal frequencies of autoreactive B cells were found in female and male mice, and no difference in the response to polyclonal stimuli of the cells of both sexes was detected. Conclusions: No differences in the composition or functionality of splenic B cells were observed that account for the different disease course in both sexes. Lupus (2011) 20, 1240-1249.
Introduction
Autoimmune diseases such as systemic lupus erythematosus (SLE) show a strong gender bias, with nine times more women than men being affected. Females are especially prone to develop lupus during the so-called child bearing years, the period in life that is characterized by enhanced production of sex hormones. 1 The risk of developing a lupus flare is further increased during pregnancy, when the endogenous levels of oestrogens further increase. 2, 3 Similar to humans, most mouse models for SLE mirror the 'preference' of lupus for females. 4 Female New Zealand Black Â New Zealand White F1 (NZB/ W F1) mice develop a lupus-like syndrome earlier and more severely than their male siblings. In the NZB/W F1 model, application of oestrogens accelerates the disease, 5, 6 while androgens, 7 anti-oestrogens 8 and ovariectomy 9 have a protective effect.
Besides sex hormones, non-hormonal factors may add to the preponderance of SLE in females. Many genes playing key roles in the regulation of the immune system, such as Foxp3, CD40Ligand (CD40L) and Toll-like receptor 7 (TLR7), are expressed on the X-chromosome. 10 It has been proposed that sex differences are attributable to a gene dosage effect, as has been shown for TLR7 and lupus. 11 One of the hallmarks of SLE is the production of autoantibodies against nuclear components, such as double-stranded deoxyribonucleic acid (dsDNA) and the SmD1 peptide (amino acids 83-119) (SmD1 ) by autoreactive B cells. 12, 13 Sexspecific factors influencing autoantibody production have been hypothesized; however, the cellular mechanisms remain elusive. Mature conventional B cells in the secondary lymphoid organs can be mainly divided into marginal zone (MZ) B cells and follicular (FO) B cells. Studies using transgenic mice suggest that autoreactive B cells are preferentially selected into the MZ B-cell compartment, which helps in maintaining immune tolerance. 14 Further experiments with genetically modified mice have provided evidence that sex hormones influence the signalling strength of the B-cell receptor and thereby modify the selection and survival of autoreactive B cells. 15 Oestrogen in particular has been shown to expand the MZ compartment, activate transgenic MZ B cells and support the production of autoantibodies. 16 Other studies have demonstrated that female cells are more easily activated by certain TLR ligands than male cells. 17 In the present study, we probed the hypothesis that the sex differences in lupus are attributable to changes in the composition and functional properties of B cells. The NZB/W F1 mouse model for SLE was used to determine autoantibody levels, size and architecture of the splenic B-cell compartments, frequency of autoreactive cells and stimulatory response in female and male B cells. We conclude that the sex discrepancy in lupus is not due to altered B-cell properties.
Materials and methods
Mice NZB/W F1 (NZB Â NZW F1) mice were obtained from the Bundesinstitut fu¨r Risikobewertung in Marienfelde, Berlin, Germany. Mice were kept in a specific pathogen-free environment at the DRFZ (German Rheumatology Research Centre), Berlin. In this mouse strain, young mice showed no urinary abnormalities. In contrast, all female mice at an age > 30 weeks demonstrated a marked proteinuria (300-2000 mg/dl) as detected by Multistix (Bayer Diagnostics, Germany) and were considered to have active nephritis and advanced lupus disease. Male mice up to 6 months of age showed no urinary abnormalities. All experiments were conducted with the approval of the local authorities Landesamtes fu¨r Gesundheit und Soziales Berlin (T0016/08).
Enzyme-linked immunosorbent assay (ELISA)
Serum samples from female and male mice were acquired monthly up to an age of 34 weeks. An anti-dsDNA and anti-SmD1 ELISA was used to analyse serum concentrations of autoantibodies. Sera were analysed in triplicates as described previously. 13, 18 Isolation of cells Spleen cells were isolated from NZB/W F1 at different ages (between 6 and 36 weeks) as specified. Mice were sacrificed by cervical dislocation. Spleens were mashed through a 70 mmØ cell strainer (BD Biosciences, Germany) and the cell suspension was washed once with PBS/BSA. Renal infiltrating cells, thymus cells, peritoneal cavity cells and bone marrow cells were isolated from aged mice. Kidneys were mashed through a 70 mmØ cell strainer (BD Biosciences, Germany) and the cell suspension was washed once with PBS/BSA. Renal lymphocytes were separated from other cells and cell detritus by density centrifugation using Percoll 1.124 (Biochrom AG, Germany) in 40% and 70% v/v dilution with RPMI media (PAA Laboratories, Germany). After centrifugation, lymphocytes were isolated and immediately washed twice with PBS/BSA. To isolate peritoneal cavity cells the peritoneum was opened and the cavity was gently washed with 10 ml cold PBS containing 0.5% BSA. Thymus cells were mashed through a 70 mmØ cell strainer; for isolation of bone marrow cells, both femurs were washed out using a syringe. Erythrocytes were eliminated by lysis using a solution containing 0.83% NH 4 Cl and 0.01 M TRIS-HCl at pH 7.5 (red blood cell lysing solution) followed by washing with PBS/BSA. Renal and thymus cells were pooled from five mice to have sufficient cell numbers for analysis.
Quantification of antibody-secreting B cells by enzyme-linked immunosorbent spot technique (ELISPOT)
For quantification of antigen-specific cells, purified FO and MZ cells were stimulated for 3 days with 10 mg/ml lipopolysaccharide (LPS) (Sigma-Aldrich, Germany) or with a combination of 10 mg/ml anti-mouse CD40 IgG clone FGK-45 and 20 ng/ml IL-4 (R&D, Germany) in complete RPMI medium containing 2 mM L-Glutamine, 100 units/ml penicillin G, 100 mg/ml streptomycin, 50 mg/ml gentamicin (PAA Laboratories, Germany), 50 mM 2-mercaptoethanol (Invitrogen, Karlsruhe, Germany), and 10% FCS (Sigma-Aldrich, Germany).
To determine dsDNA-specific antibody-secreting cells (ASC), high-binding 96-well plates (Corning, USA) were first coated with 10 mg/ml methylated-BSA (Sigma-Aldrich, Germany) for 24 h and then coated with 10 mg/ml calf thymus DNA (Sigma-Aldrich, Germany) in PBS for 24 h. For determination of anti-SmD1 (83-119) -specific ASC, high-binding 96-well plates were coated with SmD1 peptide (aa 83-119) (Department of Biochemistry, Charite´, Germany) in a concentration of 10 mg/ml in PBS overnight. To detect total ASC, plates were coated with goat anti-mouse Ig (Southern Biotech, USA). Plates were blocked with complete RPMI medium, activated cells incubated on the plates and washed off after 16-24 h. After extensive washing, bound antibodies were detected with goat antimouse Ig-biotin (Southern Biotech, USA). After washing, streptavidin-alkaline phosphatase (AP) (Roche, Germany) was added, and AP activity was visualized with developing buffer containing 5-Bromo-4-chloro-3-indol-phosphat (BCIP) and 0.6% Agarose (Sigma-Aldrich, Germany). ASC were enumerated as blue spots using an inverted microscope (Leitz, Germany). Percentages of antigen-specific B cells were calculated by dividing the number of specific ASC by the number of total ASC (%Ag-specific ASC ¼ Ag-specific ASC/total ASC Â 100).
To analyse the number of IgM and IgG-specific ASC directly ex vivo, cells were transferred in complete RPMI medium immediately after isolation without stimulation onto ELISPOT plates. Cells were washed off after 24 h of incubation and the amount of total IgM and IgG and the amount of dsDNA and SmD1 (83-119) -specific IgM and IgG producers were determined. IgM antibodies were detected with -chain-specific goat anti-mouse IgM-biotin (Southern Biotech, USA), and IgG was detected using g-chain-specific goat anti-mouse IgGbiotin (Southern Biotech, USA).
Flow cytometric (FACS) analysis of the cells
Surface markers were stained by incubating singlecell suspensions with staining antibodies for 20 min; non-bound antibodies were removed by washing with PBS/BSA. To minimize non-specific binding, Fc Receptors were blocked using a surplus of unconjugated anti-Fc-gamma antibody clone 2.4G2 (DRFZ, Berlin). The following antibodies were used: anti-mouse CD21-Cy5 clone 7G6 (DRFZ, Berlin), anti-mouse CD23-PE clone B3/ B4 (DRFZ, Berlin), and anti-mouse CD19-FITC clone 1D3 (DRFZ, Berlin). Dead cells were stained with propidium iodide (PI) (Sigma, Germany).
Cells were analysed using a Calibur flow cytometer (BD Pharmingen, Germany) and data were analysed using Flojo Software (Tree Star, USA).
Immunofluorescence
Spleens were frozen in Tissue-Tek OCT (Sakura, Staufen) compound and stored at -70 C. Frozen tissue sections of 7 mm were prepared, fixed in acetone for 10 min, and air dried. Splenic sections were pre-treated with PBS containing 3% BSA to block non-specific binding. The sections were stained with anti-mouse IgD-FITC clone 11-26c.2a (BD Pharmingen, Germany), and -chain-specific goat anti-mouse IgM-biotin (Southern Biotech, USA), Streptavidin-Rhodamin (Southern Biotech, USA), was used to visualize biotin. Finally, slides were counterstained using DAPI (2-(4-Amidinophenyl)-6-indolecarbamidine dihydrochloride) (Sigma, Germany).
Cell sorting
MZ and FO B cells were purified using a FACSDiva or FACSAria (BD Pharmingen, Heidelberg, Germany) cell sorter. To purify splenic MZ and FO B cells, splenocytes were stained for CD19, CD21, CD23 and PI. Purity of the isolated MZ and FO B cells was routinely ! 95%.
Cell proliferation
FO and MZ B cells purified by FACSsorter were labelled with carboxy-fluorescein-diacetate-succinimidyl ester (CFSE) (Molecular Probes, USA) at a final concentration of 0.5 mM for 3 min at room temperature. After labelling, the cells were stimulated with 1 mg/ml LPS, 1 mg/ml Imiquomid (Invivogen, USA) or 1 mg/ml CPG (5'-tcc atg acg ttc ctg acg tt -3', Invivogen, USA) or a combination of 10 mg/ml anti-CD40 IgG clone FGK-45 and 20 ng/ml IL-4 in complete RPMI for 3 days. Cell proliferation was analysed by CFSE dilution using flow cytometry. Alternatively, after 2 days 1 Ci 
Results
Female NZB/W F1 develop higher titres of autoantibodies which are mainly produced in the spleen
Consecutive autoantibody levels were determined in a group of female and male NZB/W F1 until age 34 weeks (n ¼ 5 in each group). As expected, female mice presented autoantibodies against the nuclear autoantigens dsDNA and SmD1 (83-119) earlier and at higher titres than their male siblings ( Figure 1A and 1B). IgM autoantibodies showed a continuous increase in female mice over the period monitored, while IgG autoantibodies showed a sharp increase at age 22-26 weeks. The increase in IgG autoantibodies was followed by the development of nephritis; at age 26 weeks the female mice had developed relevant proteinuria which was not observed in male mice until the end of the observation period (p ¼ 0.0003 at week 26, t-test).
At age 34 weeks, mice were sacrificed and the sites of antibody production determined (n ¼ 5 in each group). In the spleen, an average of 21.16 AE 13.97 Â 10 6 IgM producers per spleen were detected in female mice compared with 11.81 AE 3.64 Â 10 6 in male mice, although this difference did not reach significance (p ¼ 0.22). When comparing IgG producers, female mice had significantly more IgG ASC per spleen than male mice (3.31 AE 1.95 Â 10 6 IgG producers versus 0.12 AE 0.05 Â 10 6 , respectively, p ¼ 0.0079). In line with the higher amount of total antibody-producing cells, more than 10-fold higher amounts of IgM and IgG anti-dsDNA and anti-SmD1 (83-119) producers Figure 1 Female mice showed increased titres of autoantibodies, which were mainly produced in the spleen. A. IgM dsDNA and SmD1 (83-119) autoantibody titres in male and female NZB/W F1 mice. A significant difference was observed as early as 14 weeks of age. B. IgG dsDNA and SmD1 (83-119) autoantibody titres in NZB/W F1 mice of both sexes. Female mice exhibited a sharp increase in IgG autoantibody titres while male mice hardly developed any IgG autoantibodies in the observation period. C and D. Anti-dsDNA IgM and IgG-producing B cells per organ in female and male mice. The spleen was the major site of dsDNA autoantibody production. E and F. IgM and IgG anti-SmD1 (83-119) autoantibody production in different organs. In females more than 100-fold more autoantibody producing cells were detected compared with the bone marrow of one pair of femurs.
were found in the spleen of female mice (p < 0.01 for all), (Figure 1 C-F) . Furthermore, we observed a higher frequency of IgM autoantibodies in the spleen of female mice (dsDNA IgM antibodyforming cells (AFCs) females 0.51 AE 0.26%, males 0.06 AE 0.02%, p <0.01) (IgM SmD1 (83-119) AFCs females 0.5 AE 0.14%, males 0.01 AE 0.01%, p < 0.01). There was no significant difference in the frequency of splenic anti-dsDNA IgG autoantibody producers (anti-dsDNA IgG females 1.3 AE 0.34%, males 1.3 AE 0.76%, p ¼ 1.0), although there was a trend towards a higher frequency of anti-SmD1 (83-119) IgG secretors in female mice (females 1.2 AE 0.26%, males 0.51 AE 0.45%, p ¼ 0.0952).
The second major site of antibody production was the bone marrow of the mice. Interestingly, we found no significant difference either in the amount of IgM producers (females 164.1 AE 36.1 Â 10 3 , males 163.7 AE 112.6 Â 10 3 , p ¼ 0.4206), IgG producers (females 13.0 AE 9.4 Â 10 3 , males 14.7 AE 6.6 Â 10 3 , p ¼ 0.8413), or IgG or IgM autoantibody producers (Figure 1 C-F) . Furthermore, the bone marrow of female mice contained significantly lower frequencies of autoantibody producers than the splenic compartment (dsDNA IgM 0.1 AE 0.05%, dsDNA IgG 0.46 AE 0.06%, SmD1 (83-119) IgM 0.03 AE 0.04%, SmD1 (83-119) IgG 0.18 AE 0.12%, p <0.01 for IgM dsDNA, IgM SmD1 (83-119) and IgM dsDNA, p <0.05 for IgG SmD1 ).
In the peritoneal cavity of female mice, significantly more cells spontaneously producing dsDNA IgM autoantibodies were found than in male mice (p <0.05) (Figure 1 C-F ). Furthermore, more antibody-producing cells in the inflamed kidneys of female mice (42.2 Â 10 3 IgM AFCs and 300 IgG AFCs) were detected compared with male mice (7.8 Â 10 3 IgM AFCs and 2 IgG AFCs, pooled cells from five mice). Higher ASC numbers in females were also found in the thymus (187 Â 10 3 IgM AFCs and 297 Â 10 3 IgG AFCs compared with 110 Â 10 3 IgM AFCs and 115 Â 10 3 IgG AFCs in males, pooled cells from five mice). In line with this quantitative observation, no qualitative differences in the splenic architecture were detected using immunofluorescence (n ¼ 3 in each group). In splenic sections from young mice, FO cells (IgD high IgM low ) and MZ cells (IgD low IgM high ) showed identical distribution patterns. Immunofluorescence of splenic sections of 6-8-month-old female and male mice revealed that the majority of MZ B cells had left the marginal zone around the follicles and migrated to the interfollicular zone and into the germinal centre. In contrast, the FO B cells still mainly remained in the follicular structures around the germinal centre (Figure 3 ).
Changes in the composition of the female and male splenic B-cell compartment with progressive age

Female and male NZB/W F1 mice do not differ in the frequency of autoreactive FO or MZ cells
Splenic FO and MZ cells of healthy mice at age 8-14 weeks were purified, stimulated with LPS, and the frequency of autoreactive cells determined using ELISPOT (n ¼ 6 female and male mice analysed in four separate experiments). B cells reactive with dsDNA were mainly found in the MZ compartment (mean 0.95% of all ASC), while FO B cells contained fewer cells with specificity for dsDNA (mean 0.56%, p <0.05 Wilcoxon matched pairs test) ( Figure 4B ). SmD1 (83-119) -reactive cells were found in similar frequencies in the MZ and FO B-cell compartment, and these cells were found in lower frequencies than dsDNA B cells (mean 0.05% of all MZ ASC, 0.06% of all FO ASC, p ¼ 0.8) ( Figure 4C ). Similar results were obtained when the cells were stimulated with a combination of anti-CD40L and IL-4.
Comparison of the frequency of autoreactive B cells between female and male mice revealed no difference for dsDNA or SmD1 (83-119) -reactive MZ and FO B cells ( Figure 4D-F) . In order to compare different experiments, a stimulation ratio was calculated, with a value of 1 indicating identical frequencies of autoreactive cells. For LPS-activated female MZ cells, the ratio for dsDNA-reactive cells was 1.015 AE 0.181 compared with 0.985 AE 0.160 for Figure 4D ). Similar result were obtained for SmD1 (83-119)reactive cells ( Figure 4E ). Neither variation of the stimulation regime (LPS or anti-CD40L + IL-4) nor of the age of the mice (female mice aged 22 weeks and older with nephritis as indicated by proteinuria and age-matched male mice, n ¼ 4) resulted in a significant difference in the frequency of autoreactive splenic B MZ or FO B cells between the two sexes of NZB/W F1 mice.
B cells of female and male origin do not differ in their activation threshold or in their proliferative response upon stimulation
In order to compare the activation threshold of female and male B cells, purified FO and MZ cells from pre-diseased mice (age 12 weeks) were stimulated with LPS, CpG, Imiquomid and anti-CD40L + IL-4 (pooled cells from eight mice, four separate experiments). Using CFSE dilution and [ 3 H]-Thymidin incorporation, there were no differences in the activation threshold or proliferative response either upon stimulation with various TLR ligands (LPS, CpG, Imiquomid) or upon stimulation with anti-CD40L and IL-4 ( Figure 5A-D) . Comparing the different experiments by calculating the proliferative ratio of female and male cells (with 1 indicating identical proliferation), no significant difference was detected either for MZ ( Figure 5E ) or FO B cells (data not shown). In line with these observations, no difference in the number of APCs upon stimulation of purified female and male FO and MZ B cells with LPS or anti-CD40L + IL-4 was observable ( Figure 5F and G) .
Discussion
In the present study we analysed the composition of the splenic B-cell compartments, the frequency of autoreactive B cells and the activation threshold of B cells from female and male NZB/W F1 mice.
No sex-specific differences prior to overt lupus disease were evident. One hallmark of lupus is the occurrence of autoantibodies against nuclear components such as dsDNA or SmD1 (83-119) ; 12, 13, 19 however, the exact events leading to the development of SLE are ill defined. Notably, the disease shows a strong sex bias, as SLE affects nine times more women than men, and murine models almost unequivocally reflect this sex bias. 1, 4 In the NZB/W F1 model, female mice succumb to a lupus-like disorder earlier than their male siblings, show a more accelerated disease course and die at a younger age. 4 Given the small genetic difference between female and male NZB/W F1 mice and the overtly different disease course, we found it interesting to determine the cellular basis for the latter. As expected, female NZB/W F1 mice developed autoantibodies earlier and at higher levels than male mice. In line with the autoantibody levels, female mice presented signs of nephritis at a time point when their male siblings showed no urinary abnormalities at all. In female mice, the spleen turned out to be the major site of (auto)antibody-producing cells, containing more than 100 times more total antibody producers and autoantibody producers than the bone marrow of two femurs. Given that 12-16% of the total bone marrow is found in the femurs of mice, 20 even extrapolating the amount of ASC in the femurs to the total bone marrow mass falls short of the amount of splenic antibody producers of female NZB/W F1.
The splenic B cells were further analysed to determine whether a sex-specific difference in B-cell composition or functionality was responsible for the observed difference in autoantibody levels and disease course. In the NZB/W F1 and other mouse models of lupus, an expansion of the MZ B-cell compartment has been described and associated with SLE. 21, 22 Consistent with these reports, we found an expanded MZ B-cell compartment, with 15-22% of the splenic B cells presenting an MZ B-cell phenotype. However, neither a quantitative nor qualitative difference in the splenic B-cell compartments was observed when comparing female and male NZB/W F1 mice. Subtle differences arose in the course of the disease, but those differences are likely a consequence of the accelerated disease in females and thus not the primary reason for the clinical sex difference. Similarly, we recently reported that in pre-diseased young NZB/W F1 mice there is no difference in the frequency of autoreactive B1a B cells in the peritoneal cavity, which does, however, arise in the course of the generalized autoimmunity in these mice. 23 In previous reports, MZ B cells have been shown to be more easily activated than FO B cells and to harbour B cells with autoreactive specificity. 14, 21, 24 Our present study is in line with these previous findings, as we found more dsDNA-reactive cells in the MZ than the FO compartment, and MZ B cells proved to be more easily activated and to proliferate more upon stimulation.
Sex-specific factors such as hormones have been reported to be involved in the selection and survival of autoreactive B cells. 15, 16 We determined whether NZB/W F1 mice of both sexes would differ in the frequency or subset distribution of autoreactive B cells. In the present study, no differences in the percentage or subset distribution of B cells autoreactive with the two canonical SLE autoantigens, dsDNA and SmD1 (83-119) , were detected. Previous reports described that oestrogen leads to an expansion of the MZ B-cell compartment and selection of autoreactive B cells into the MZ B-cell pool. 16 It was shown that the expansion of the MZ compartment was mediated via the oestrogen-a and -b receptors, while the increased survival of high-affinity anti-dsDNA B cells was mediated solely via the oestrogen-a receptor. 25 The discrepancy between our results and these reports may be due to the model used, as these previous studies have used genetically modified mice and the B-cell selection of transgenic B cells might be skewed artificially. On the other hand, a limitation of our study is that we had no means of determining the fine specificity and affinity of the autoreactive cells analysed. Therefore, our approach using the ELISPOT technique to determine the frequency of autoreactive cells could have missed a hypothetical difference in the affinity of the autoantibodies produced.
B cells in SLE are known to be hyper-reactive, and differences in the activation threshold of female and male cells have been claimed. 17, 26 Activation of B cells via intracellular TLRs sensing RNA and DNA (TLR7 and TLR9) is likely to play a pivotal role in the pathogenesis of SLE. In addition, B cells producing autoantibodies in SLE display the features of B cells that have received T-cell help. 27 In our experiments, no difference in the proliferation of female and male B cells was observed, neither upon stimulation via the intracellular TLRs 7 and 9, the extracellular LPS-sensing TLR4, nor upon activation with anti-CD40 plus IL-4. These results indicate that female and male B cells do not differ in their activation threshold and proliferative response upon activation.
In summary, we show that female and male NZB/W F1 mice do not differ in their splenic B-cell composition, activation threshold or frequency of dsDNA-or SmD1 (83-119) autoreactive B cells prior to disease development. Therefore the question remains: why do female mice show earlier and higher autoantibody production and an accelerated disease course? Based on our results, we speculate that sex-specific differences in the activation of the immune cascade downstream of the analysed B-cell properties may account for the overt clinical differences. Oestrogens have been shown to act on T cells, which may in turn lead to a stronger B-cell activation. 28 In addition, sex hormones may influence cell survival and the amount of antibodies produced. 29 Others have reported a direct effect of oestrogen on the expression of transcription factors, which may further promote progression of autoimmunity. 30 Considering the marked clinical difference between females and males, analysing sex-specific differences will allow further future insights into the pathogenesis of lupus.
